These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 10411054)

  • 1. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.
    Shipley WU; Kaufman DS; Heney NM; Althausen AF; Zietman AL
    J Urol; 1999 Aug; 162(2):445-50; discussion 450-1. PubMed ID: 10411054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of radiation therapy and combined-modality treatment for bladder cancer.
    Rödel C
    Strahlenther Onkol; 2004 Nov; 180(11):701-9. PubMed ID: 15549188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer.
    Douglas RM; Kaufman DS; Zietman AL; Althausen AF; Heney NM; Shipley WU
    Semin Oncol; 1996 Oct; 23(5):614-20. PubMed ID: 8893872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
    Mak RH; Zietman AL; Heney NM; Kaufman DS; Shipley WU
    BJU Int; 2008 Nov; 102(9 Pt B):1345-53. PubMed ID: 19035903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective bladder preservation by combination treatment of invasive bladder cancer.
    Kaufman DS; Shipley WU; Griffin PP; Heney NM; Althausen AF; Efird JT
    N Engl J Med; 1993 Nov; 329(19):1377-82. PubMed ID: 8413433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
    Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
    Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
    Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
    Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of bladder cancer trials in the Radiation Therapy Oncology Group.
    Shipley WU; Kaufman DS; Tester WJ; Pilepich MV; Sandler HM;
    Cancer; 2003 Apr; 97(8 Suppl):2115-9. PubMed ID: 12673704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
    Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
    Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can chemo-radiotherapy plus transurethral tumor resection make cystectomy unnecessary for invasive bladder cancer?
    Shipley WU; Kaufman DS; Heney NM
    Oncology (Williston Park); 1990 Jul; 4(7):25-32; discussion 32-4, 39. PubMed ID: 2143938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
    Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimodality treatment and selective organ preservation for bladder cancer.
    Rödel C; Weiss C; Sauer R
    J Clin Oncol; 2006 Dec; 24(35):5536-44. PubMed ID: 17158539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
    Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
    J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined modality treatment with selective bladder conservation for invasive bladder cancer: long-term tolerance in the female patient.
    Kachnic LA; Shipley WU; Griffin PP; Zietman AL; Kaufman DS; Althausen AF; Heney NM
    Cancer J Sci Am; 1996; 2(2):79-84. PubMed ID: 9166504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.